Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
The production suspension impacts commercial and clinical trial supply
Upon closing, the Quakertown business will become an independent company called Microsize
Subscribe To Our Newsletter & Stay Updated
